Wire · opportunities
Nektar Discloses Phase 2b Data for REZPEG in Severe Alopecia Areata
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 October 2026 · Fusion42 review
Nektar Therapeutics announced Phase 2b results for REZPEG in severe alopecia areata, highlighting a novel regulatory T-cell stimulation approach with promising maintenance of hair coverage post-treatment and planning Phase 3 initiation in early 2027. The drug offers a potential non-JAK inhibitor option amid competition including an existing FDA-approved JAK inhibitor and Pfizer's ongoing Phase 2b/3 trial.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a chance to offer a non-JAK therapy to severe alopecia areata patients who cannot tolerate existing options. Early Phase 2b signals let you prioritise Phase 3 dose selection now before Pfizer's larger trial results land.
◆ Coverage
1 source · 2 Oct 2026
◆ Related on Wire
◆ Topics